Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “antagonist”

678 pharma patents match "antagonist" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 678
Index total 30,257
Page 5 / 29

Quick answer

This filtered view shows 678 pharmaceutical patents matching "antagonist" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

678 results for “antagonist” · 30,257 patents in full index Clear search

  1. US 11337971

    Dopamine D3 receptor selective antagonists/partial agonists and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 24, 2022 · Expires May 19, 2042

    granted
  2. US 11337988

    Use of ouabain antagonists to inhibit viral infection

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted May 24, 2022 · Expires May 19, 2042

    granted
  3. US 11311549

    Corticotropin releasing factor receptor antagonists

    SPRUCE BIOSCIENCES, INC. · Granted Apr 26, 2022 · Expires Apr 21, 2042

    granted
  4. US 11306150

    Method of identifying a P-selectin glycoprotein ligand-1 (PSGL-1) antagonist

    Five Prime Therapeutics, Inc. · Granted Apr 19, 2022 · Expires Apr 14, 2042

    granted
  5. US 11299476

    Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 12, 2022 · Expires Apr 7, 2042

    granted
  6. US 11253572

    Use of a VEGF antagonist to treat angiogenic eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 22, 2022 · Expires Feb 17, 2042

    granted
  7. US 11247969

    Biphenyl compounds useful as muscarinic receptor antagonists

    Theravance Biopharma R&D IP, LLC · Granted Feb 15, 2022 · Expires Feb 10, 2042

    granted
  8. AR 120033

    ANTAGONISTA RADIOMARCADO DE GRPR PARA USO COMO AGENTE TERAGNÓSTICO

    ADVANCED ACCELERATOR APPLICATIONS ITALY SRL [IT] · Granted Jan 26, 2022 · Expires Jan 21, 2042

    granted
  9. AR 119975

    MÉTODOS PARA RADIOMARCAR ANTAGONISTAS DE GRPR Y SUS KITS

    ADVANCED ACCELERATOR APPLICATIONS ITALY SRL [IT] · Granted Jan 26, 2022 · Expires Jan 21, 2042

    granted
  10. US 11229681

    Dominant-negative FGF2 antagonists

    The Regents of the University of California · Granted Jan 25, 2022 · Expires Jan 20, 2042

    granted
  11. US 11214621

    Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 4, 2022 · Expires Dec 30, 2041

    granted
  12. US 11208397

    Small molecule antagonists of sumo related modification of CRMP2 and uses thereof

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Dec 28, 2021 · Expires Dec 23, 2041

    granted
  13. US 11202784

    Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency

    Corcept Therapeutics Incorporated · Granted Dec 21, 2021 · Expires Dec 16, 2041

    granted
  14. US 11186577

    Vasopressin receptor antagonists and products and methods related thereto

    BLACKTHORN THERAPEUTICS, INC. · Granted Nov 30, 2021 · Expires Nov 25, 2041

    granted
  15. US 11185554

    Method of use of eritoran as a TLR4 antagonist for treatment of ebola and Marburg disease

    The Board of Regents of the University of Texas System · Granted Nov 30, 2021 · Expires Nov 25, 2041

    granted
  16. US 11179370

    Cannabinoid receptor antagonists/inverse agonists useful for treating disease conditions, including metabolic disorders and cancers

    Jenrin Discovery, LLC · Granted Nov 23, 2021 · Expires Nov 18, 2041

    granted
  17. US 11173118

    Emulsion formulations of an NK-1 receptor antagonist and uses thereof

    Heron Therapeutics, Inc. · Granted Nov 16, 2021 · Expires Nov 11, 2041

    granted
  18. US 11155523

    Biphenyl compound as CCR2/CCR5 receptor antagonist

    Medshine Discovery Inc. · Granted Oct 26, 2021 · Expires Oct 21, 2041

    granted
  19. US 11154556

    Methods of treating solid tumors with CCR2 antagonists

    The Regents of the University of California · Granted Oct 26, 2021 · Expires Oct 21, 2041

    granted
  20. US 11141452

    Bifunctional compounds for relief of pain comprising an opioid receptor agonist moiety and a NK1 receptor antagonist moiety and methods for treating pain

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Oct 12, 2021 · Expires Oct 7, 2041

    granted
  21. US 11136315

    CXCR2 antagonist

    Medshine Discovery Inc. · Granted Oct 5, 2021 · Expires Sep 30, 2041

    granted
  22. US 11124489

    EPAC antagonists

    The Board of Regents of the University of Texas System · Granted Sep 21, 2021 · Expires Sep 16, 2041

    granted
  23. US 11124504

    Kappa opioid receptor antagonists and products and methods related thereto

    BLACKTHORN THERAPEUTICS, INC. · Granted Sep 21, 2021 · Expires Sep 16, 2041

    granted
  24. US 11111270

    Inhibitor of apoptosis protein (IAP) antagonists

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Sep 7, 2021 · Expires Sep 2, 2041

    granted